Politico: Drugmakers defy Trump’s call to drop prices
July 5, 2018
Despite Trump’s promises to stand up to the pharmaceutical industry and rein in drug costs, drug prices continue to increase. Rather than take real action, Trump has only offered empty words and an ineffective drug plan that could actually make medications more expensive for millions of Americans.
Politico: Drugmakers defy Trump's call to drop prices
By Sarah Karlin-Smith
President Donald Trump in May said that drugmakers would soon announce “massive” price cuts, and his administration rolled out a plan to bring down the cost of medicines. But the companies don’t appear to have gotten that message.
Bayer raised the price of two cancer drugs by hundreds of dollars in May and Novartis followed by boosting four pricey treatments in June. Pfizer, one of the largest U.S. pharmaceutical companies, announced increases on more than 41 products this week. They weren't alone.
A Wells Fargo report found 104 price increases in June and the first two days of July, with an average jump of 31.5 percent and a median increase of 9.4 percent. That followed 48 increases in May. The list price hikes don’t factor in discounts that companies may provide to some insurance companies and patients.
The across-the-board increases cast doubt on whether Trump and Health and Human Services Secretary Alex Azar can pressure manufacturers to voluntarily drop prices without the threat of specific consequences.
Azar, in a May 14 speech rolling out the drug pricing plan, asserted Trump had “laid down a marker about the need for reform” and hinted there would be consequences for companies that raised prices for reasons other than inflation or a change in clinical benefit. “I can tell you I wouldn’t have wanted to be the one to do that,” the former Eli Lilly executive said.
By signing up you agree to receive email newsletters or alerts from POLITICO. You can unsubscribe at any time.
Last week, Azar told the Senate Finance Committee he “hope[d]” companies will “exercise restraint” with midyear price increases.
Most of the recent price increases are well above the current U.S. inflation rate, which is less than 3 percent.
Health policy experts say one flaw with the administration’s plan is the lack of any serious follow-through.